People with migraines and comorbid mood disorders often need treatments that address both conditions, as well as management of sleep, stress, and lifestyle issues.
Compared with patients not reporting headache, patients with HRH had significantly greater differences in pre- and post-BUN values.
A significantly lower percentage of patients receiving a 70-mg or 140-mg dose of erenumab had severe disability during treatment compared with placebo.
The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine.
Fremanezumab treatment may be efficacious in reducing the number of monthly headache days in the long-term in people with chronic migraine.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
Few patients were found to take triptan medications to treat acute migraine, and a majority of those who had, discontinued the treatment due to side effects.
Lasmiditan was found to be more effective compared with placebo in eliminating pain and other symptoms associated with headache in individuals with migraine.
Investigator analyzed the number of scripts and days of therapy in patients with migraine to determine use and frequency of overuse.
Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.
DFN-11, a 3 mg subcutaneous sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine.
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure